Ken Griffin Protalix Bio Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 61,100 shares of PLX stock, worth $103,259. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,100

Previous 55,100 10.89%

Holding current value

$103,259

Previous $64,000 3.13%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.9 - $1.17 $65,871 - $85,632	73,190 Added 396.31%	91,658 $93,000
Q2 2024 Aug 14, 2024	SELL	$1.1 - $1.32 $21,252 - $25,502	-19,320 Reduced 51.13%	18,468 $21,000
Q1 2024 May 15, 2024	BUY	$1.22 - $1.82 $46,101 - $68,774	37,788 New	37,788 $47,000
Q3 2023 Nov 14, 2023	BUY	$1.49 - $2.02 $38,164 - $51,740	25,614 New	25,614 $42,000
Q1 2023 May 15, 2023	BUY	$1.37 - $2.16 $119,520 - $188,440	87,241 Added 70.18%	211,548 $444,000
Q4 2022 Feb 14, 2023	BUY	$1.0 - $1.37 $65,750 - $90,077	65,750 Added 112.28%	124,307 $170,000
Q3 2022 Nov 14, 2022	SELL	$1.03 - $1.24 $1,398 - $1,683	-1,358 Reduced 2.27%	58,557 $61,000
Q2 2022 Aug 15, 2022	BUY	$1.02 - $1.56 $31,518 - $48,204	30,900 Added 106.5%	59,915 $65,000
Q4 2021 Feb 14, 2022	BUY	$0.81 - $1.33 $3,296 - $5,413	4,070 Added 16.32%	29,015 $24,000
Q3 2021 Nov 15, 2021	SELL	$1.31 - $1.87 $119,132 - $170,059	-90,941 Reduced 78.47%	24,945 $34,000
Q2 2021 Aug 16, 2021	BUY	$1.86 - $6.22 $186,212 - $622,709	100,114 Added 634.76%	115,886 $221,000
Q1 2021 May 17, 2021	SELL	$3.58 - $6.45 $29,624 - $53,373	-8,275 Reduced 34.41%	15,772 $70,000
Q2 2020 Aug 14, 2020	BUY	$2.19 - $4.5 $52,662 - $108,211	24,047 New	24,047 $92,000

Others Institutions Holding PLX

# of Institutions

Shares Held

3.58M

Call Options Held

61.1K

Put Options Held

36.2K

View Full List

About Protalix BioTherapeutics, Inc.

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $84.1M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

More about PLX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account